Company Description
Microbot Medical Inc. is a medical device company that focuses on transforming endovascular procedures through advanced robotic technology.
The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, endovascular, and neurovascular operations.
It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter.
The company has a collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system; and Emory University, in connection with autonomous robotics in endovascular procedures.
Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts
| Country | United States |
| Founded | 2010 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Harel Gadot |
Contact Details
Address: 175 Derby Street, Bld. 27 Hingham, Massachusetts 02043 United States | |
| Phone | 781 875 3605 |
| Website | microbotmedical.com |
Stock Details
| Ticker Symbol | MBOT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000883975 |
| CUSIP Number | 59503A204 |
| ISIN Number | US59503A2042 |
| Employer ID | 94-3078125 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Harel Gadot | Co-Founder, President, Chief Executive Officer and Chairman |
| Rachel Vaknin | Chief Financial Officer |
| Dr. Simon Sharon MBA, MSc | Chief Technology Officer and GM of Microbot Israel |
| Dr. Juan Diaz-Cartelle | Chief Medical Officer |
| Michal Ahuvia | Director of Operations |
| Christina Bailey | Vice President of Sales |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2025 | 10-Q | Quarterly Report |
| Nov 7, 2025 | SCHEDULE 13G/A | Filing |
| Nov 5, 2025 | 8-K | Current Report |
| Oct 31, 2025 | SCHEDULE 13G/A | Filing |
| Oct 28, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Oct 28, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Oct 16, 2025 | 8-K | Current Report |
| Oct 14, 2025 | 8-K | Current Report |
| Oct 14, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Oct 14, 2025 | S-3 | Registration statement under Securities Act of 1933 |